RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Imactis

Company

Content

Owners

History

2023: GE HealthCare bought Imactis

On January 9, 2023, GE HealthCare announced the acquisition of Imactis, a developer of interventional tomography guidance technology. The companies declined to publicly disclose the financial terms of the deal.

The French company Imactis, founded in 2009, is developing the CT-Navigation system. Ergonomic, versatile solution provides stereotactic needle guidance. This enables intuitive pre-planning and continuous monitoring over a wide range of procedures.

GE HealthCare intends to fund it with its own funds. It still depends on the usual terms of the closure of the deal, including a government audit in France. The acquisition marks the first M&A experience for GE HealthCare since it became a standalone company in early January 2023.

GE HealthCare buys technology developer for CT operations
File:Aquote1.png
We are pleased to take this step in strengthening our intervention referral proposal for patients and clients. The Imactis CT navigation system is designed to improve the workflow of interventional radiologists and hospitals by improving the accuracy of procedures while helping to reduce procedure time and radiation dose for patients and physicians, commented Ian Makela, President and CEO of Imaging.
File:Aquote2.png

In a press release, GE HealthCare called intervention CT imaging capabilities a "high-opportunity growth driver" through 2025. The Imactis acquisition opens up access to this market. GE HealthCare intends to extend Imactis technology to its image-guided therapy business and drive further growth. In addition, GE HealthCare expects needs for intervention techniques to grow in all areas of health care. These include oncology, cardiology, urology, nephrology and gastroenterology.

CT-Navigation developed by Imactis consists of an integrated workstation software , for guidance and a one-time kit for conducting procedures. As of January 12, 2023, it is approved in accordance with the EU MDR and has a permit FDA for use in. USA GE HealthCare expects to provide significant global opportunities for this platform at existing client sites.[1]

Notes